Psoriasis.
Psoriasis is one of the most common chronic inflammatory disorders with a strong genetic background. Recent progress in the understanding of both the immunological as well as the genetic basis has provided an unprecedented opportunity to move scientific insights from the bench to bedside. Based on insights from laboratory research, targeted immunotherapies are now available for the benefit of patients suffering from psoriasis. The success of these therapies has validated insights into disease pathogenesis and also provides the opportunity to increase our understanding about the pathways underpinning autoimmune-type inflammation in the skin.
Nestle
Frank O
FO
St. John's Institute of Dermatology, Division of Genetics and Molecular Medicine, King's College London School of Medicine at Guy's, Guy's Hospital, London, UK. frank.nestle@kcl.ac.uk
D000818:Animals; D001327:Autoimmune Diseases / Q000235:genetics / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D002908:Chronic Disease; D006801:Humans; D007167:Immunotherapy; D011565:Psoriasis / Q000235:genetics / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D012867:Skin / Q000276:immunology* / Q000473:pathology